Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Recent Advances in Nanotechnology for Targeted Protein Degradation. Local targets link to admitted publications; unresolved targets remain external evidence.
Progress and Challenges in Targeted Protein Degradation for Neurodegenerative Disease Therapy
10.1021/acs.jmedchem.2c00844 · 2022 · External reference
Application of Novel Degraders Employing Autophagy for Expediting Medicinal Research
10.1021/acs.jmedchem.2c01712 · 2023 · External reference
Unconventional PROTACs for Targeted Protein Degradation in Cancer Therapy
10.1002/anie.202507702 · 2025 · External reference
A deep proteome and transcriptome abundance atlas of 29 healthy human tissues
10.15252/msb.20188503 · 2019 · External reference
Small molecules, big impact: 20 years of targeted therapy in oncology
10.1016/s0140-6736(20)30164-1 · 2020 · External reference
Small-Molecule Kinase Inhibitors for the Treatment of Nononcologic Diseases
10.1021/acs.jmedchem.0c01511 · 2021 · External reference
Small-Molecule Inhibitors of Necroptosis: Current Status and Perspectives
10.1021/acs.jmedchem.9b01317 · 2019 · External reference
The role of reversible and irreversible covalent chemistry in targeted protein degradation
10.1016/j.chembiol.2021.03.005 · 2021 · External reference
Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
10.1038/s41392-021-00572-w · 2021 · External reference
Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs
10.1016/j.ebiom.2018.09.005 · 2018 · External reference
Small-Molecule PROTACS: New Approaches to Protein Degradation
10.1002/anie.201507978 · 2016 · External reference
Drugging Undruggable Molecular Cancer Targets
10.1146/annurev-pharmtox-010715-103440 · 2016 · External reference
Targeted protein degradation: mechanisms, strategies and application
10.1038/s41392-022-00966-4 · 2022 · External reference
Induced protein degradation: an emerging drug discovery paradigm
10.1038/nrd.2016.211 · 2016 · External reference
PROTAC targeted protein degraders: the past is prologue
10.1038/s41573-021-00371-6 · 2022 · External reference
Lysosome-targeting chimaeras for degradation of extracellular proteins
10.1038/s41586-020-2545-9 · 2020 · External reference
Elucidating the cellular determinants of targeted membrane protein degradation by lysosome-targeting chimeras
10.1126/science.adf6249 · 2023 · External reference
Allele-selective lowering of mutant HTT protein by HTT–LC3 linker compounds
10.1038/s41586-019-1722-1 · 2019 · External reference
Perspectives of autophagy-tethering compounds (ATTECs) in drug discovery
10.1016/j.medp.2023.100004 · 2024 · External reference
Targeted protein degradation via intramolecular bivalent glues
10.1038/s41586-024-07089-6 · 2024 · External reference
Chasing molecular glue degraders: screening approaches
10.1039/d2cs00197g · 2022 · External reference
Targeted clearance of mitochondria by an autophagy-tethering compound (ATTEC) and its potential therapeutic effects
10.1016/j.scib.2023.10.021 · 2023 · External reference
Degradation of lipid droplets by chimeric autophagy-tethering compounds
10.1038/s41422-021-00532-7 · 2021 · External reference
Applications of covalent chemistry in targeted protein degradation
10.1039/d2cs00362g · 2022 · External reference
Homobivalent, Trivalent, and Covalent PROTACs: Emerging Strategies for Protein Degradation
10.1021/acs.jmedchem.2c00728 · 2022 · External reference
Emerging degrader technologies engaging lysosomal pathways
10.1039/d2cs00624c · 2022 · External reference
ATNC: Versatile Nanobody Chimeras for Autophagic Degradation of Intracellular Unligandable and Undruggable Proteins
10.1021/jacs.3c08843 · 2023 · External reference
HaloPROTACS: Use of Small Molecule PROTACs to Induce Degradation of HaloTag Fusion Proteins
10.1021/acschembio.5b00442 · 2015 · External reference
Ispinesib as an Effective Warhead for the Design of Autophagosome-Tethering Chimeras: Discovery of Potent Degraders of Nicotinamide Phosphoribosyltransferase (NAMPT)
10.1021/acs.jmedchem.1c02001 · 2022 · External reference
Degradation of Cyclin-Dependent Kinase 9/Cyclin T1 by Optimized Microtubule-Associated Protein 1 Light Chain 3 Beta-Recruiting Coumarin Analogs
10.1021/acs.jmedchem.3c00828 · 2023 · External reference
Discovery of ARD-2585 as an Exceptionally Potent and Orally Active PROTAC Degrader of Androgen Receptor for the Treatment of Advanced Prostate Cancer
10.1021/acs.jmedchem.1c00900 · 2021 · External reference
Development of Dual-Receptor Lysosome-Targeting Chimeras for Protein Degradation
10.1021/jacs.5c13695 · 2025 · External reference
Proteolysis-targeting chimera (PROTAC) delivery system: advancing protein degraders towards clinical translation
10.1039/d1cs00762a · 2022 · External reference
Targeted protein degradation by PROTACs
10.1016/j.pharmthera.2017.02.027 · 2017 · External reference
Inducible In Vivo Silencing of Brd4 Identifies Potential Toxicities of Sustained BET Protein Inhibition
10.1016/j.celrep.2014.08.025 · 2014 · External reference
Discovery of ARD-2051 as a Potent and Orally Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor for the Treatment of Advanced Prostate Cancer
10.1021/acs.jmedchem.3c00405 · 2023 · External reference
Discovery of BWA-522, a First-in-Class and Orally Bioavailable PROTAC Degrader of the Androgen Receptor Targeting N-Terminal Domain for the Treatment of Prostate Cancer
10.1021/acs.jmedchem.3c00585 · 2023 · External reference
Discovery of Novel SHP2 ATTEC Degraders against Pancreatic Ductal Adenocarcinoma Harboring KRAS(G12D) Mutations
10.1021/acs.jmedchem.4c02682 · 2025 · External reference
Critical assessment of LC3/GABARAP ligands used for degrader development and ligandability of LC3/GABARAP binding pockets
10.1038/s41467-024-54409-5 · 2024 · External reference
Polymeric nanoparticle-based nanovaccines for cancer immunotherapy
10.1039/d2mh01358d · 2023 · External reference
Controlled Refolding of Denatured IL-12 Using In Situ Antigen-Capturing Nanochaperone Remarkably Reduces the Systemic Toxicity and Enhances Cancer Immunotherapy
10.1002/adma.202309927 · 2024 · External reference
Tailoring a Nanochaperone to Regulate α-Synuclein Assembly
10.1002/anie.202200192 · 2022 · External reference
Liposome-mediated PD-L1 multivalent binding promotes the lysosomal degradation of PD-L1 for T cell-mediated antitumor immunity
10.1016/j.biomaterials.2022.121841 · 2022 · External reference
Allosteric synthetic antibody (Allo-SyAb) for improved cancer immunotherapy
10.1016/j.cej.2023.142374 · 2023 · External reference
Synergistic therapy for pancreatic cancer by deactivating cancer-associated fibroblasts and driving T-cell migration into tumor microenvironment using nanochaperone delivery system
10.1016/j.bioactmat.2025.06.010 · 2025 · External reference
A Dynamic Covalent Bonding-based Nanoplatform for Intracellular Co-Delivery of Protein Drugs and Chemotherapeutics with Enhanced Anti-Cancer Effect
10.1007/s10118-024-3090-z · 2024 · External reference
Bioactive Nanomaterials for Cancer Immunotherapy
10.1007/s10118-026-3567-z · 2026 · External reference
In vivo assembly enhanced binding effect augments tumor specific ferroptosis therapy
10.1038/s41467-023-44665-2 · 2024 · External reference
Antioxidant Glycopolypeptide Micelles for Targeted Delivery of Silibinin to Hepatocellular Carcinoma Cells
10.1007/s10118-025-3429-0 · 2025 · External reference
Nanochaperones Based on Hydrophobic Interaction and Coordination Inhibit Protein Misfolding and Fibrillation
10.1007/s10118-024-3169-6 · 2024 · External reference
Protein degradation technology: a strategic paradigm shift in drug discovery
10.1186/s13045-021-01146-7 · 2021 · External reference
Targeted protein degradation in the transmembrane and extracellular space
10.1126/science.adx5094 · 2025 · External reference
Chemistries of bifunctional PROTAC degraders
10.1039/d2cs00220e · 2022 · External reference
Development of Novel Silicon-Based Hydrophobic Tags (SiHyT) for Targeted Proteins Degradation
10.1021/acs.jmedchem.4c02273 · 2024 · External reference
Recent advances and clinical prospects of non-viral brain-targeted gene delivery systems
10.1063/5.0255745 · 2025 · External reference
Targeting Lysosomal Degradation Pathways: New Strategies and Techniques for Drug Discovery
10.1021/acs.jmedchem.0c01689 · 2021 · External reference
An Engineered Nanovesicles-Based Lysosome-Targeting Protein Degradation Platform (NV-TACs) for Cancer Immunotherapy
10.1021/jacs.5c17801 · 2026 · External reference
Antibody targeting of E3 ubiquitin ligases for receptor degradation
10.1038/s41586-022-05235-6 · 2022 · External reference
Advances in Peptide-Based Chimeric Strategies for Targeted Protein Degradation
10.1021/acs.jmedchem.5c02379 · 2025 · External reference
Targeted degradation of α-synuclein aggregates in Parkinson’s disease using the AUTOTAC technology
10.1186/s13024-023-00630-7 · 2023 · External reference
The AUTOTAC chemical biology platform for targeted protein degradation via the autophagy-lysosome system
10.1038/s41467-022-28520-4 · 2022 · External reference
AUTACs: Cargo-Specific Degraders Using Selective Autophagy
10.1016/j.molcel.2019.09.009 · 2019 · External reference
Structural and Physicochemical Features of Oral PROTACs
10.1021/acs.jmedchem.4c01017 · 2024 · External reference
Linker-Dependent Folding Rationalizes PROTAC Cell Permeability
10.1021/acs.jmedchem.2c00877 · 2022 · External reference
Structural basis of PROTAC cooperative recognition for selective protein degradation
10.1038/nchembio.2329 · 2017 · External reference
Ternary complex dissociation kinetics contribute to mutant-selective EGFR degradation
10.1016/j.chembiol.2023.01.007 · 2023 · External reference
Tracking the PROTAC degradation pathway in living cells highlights the importance of ternary complex measurement for PROTAC optimization
10.1016/j.chembiol.2023.06.002 · 2023 · External reference
BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design
10.1038/s41589-019-0294-6 · 2019 · External reference
SPR-Measured Dissociation Kinetics of PROTAC Ternary Complexes Influence Target Degradation Rate
10.1021/acschembio.9b00092 · 2019 · External reference
Snapshots and ensembles of BTK and cIAP1 protein degrader ternary complexes
10.1038/s41589-020-00686-2 · 2020 · External reference
Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead
10.1016/j.chembiol.2017.09.010 · 2018 · External reference
PROTAC-induced protein structural dynamics in targeted protein degradation
10.7554/elife.101127 · 2025 · External reference
Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase
10.1038/s41467-018-08027-7 · 2019 · External reference
PROTAC-Mediated Degradation of Bruton’s Tyrosine Kinase Is Inhibited by Covalent Binding
10.1021/acschembio.8b01094 · 2019 · External reference
Targeted Biomolecule Regulation Platform: A Split-and-Mix PROTAC Approach
10.1021/jacs.2c12824 · 2023 · External reference
Clinical considerations for the design of PROTACs in cancer
10.1186/s12943-022-01535-7 · 2022 · External reference
The Role of MDM2 Amplification and Overexpression in Tumorigenesis
10.1101/cshperspect.a026336 · 2016 · External reference
Functional Genomics Identify Distinct and Overlapping Genes Mediating Resistance to Different Classes of Heterobifunctional Degraders of Oncoproteins
10.1016/j.celrep.2020.108532 · 2021 · External reference
Expanding the arsenal of E3 ubiquitin ligases for proximity-induced protein degradation
10.1016/j.chembiol.2021.04.007 · 2021 · External reference
Nano Proteolysis Targeting Chimeras (PROTACs) with Anti-Hook Effect for Tumor Therapy
10.1002/anie.202308049 · 2023 · External reference
Sulfatase-Induced In Situ Formulation of Antineoplastic Supra-PROTACs
10.1021/jacs.4c00826 · 2024 · External reference
Targeted Degradation of PD-L1 and Activation of the STING Pathway by Carbon-Dot-Based PROTACs for Cancer Immunotherapy
10.1002/anie.202218128 · 2023 · External reference
Selective Protein of Interest Degradation through the Split-and-Mix Liposome Proteolysis Targeting Chimera Approach
10.1021/jacs.3c05948 · 2023 · External reference
DNA Tetrahedron-Driven Multivalent Proteolysis-Targeting Chimeras: Enhancing Protein Degradation Efficiency and Tumor Targeting
10.1021/jacs.4c16438 · 2025 · External reference
Covalent LYTAC Enabled by DNA Aptamers for Immune Checkpoint Degradation Therapy
10.1021/jacs.3c03899 · 2023 · External reference
Covalently Engineered Nanobody Chimeras for Targeted Membrane Protein Degradation
10.1021/jacs.1c08521 · 2021 · External reference
Semiconducting Polymer Nanoparticles with Surface-Mimicking Protein Secondary Structure as Lysosome-Targeting Chimaeras for Self-Synergistic Cancer Immunotherapy
10.1002/adma.202203309 · 2022 · External reference
Phototriggered LYTAC: Photoactive Bispecific Aptamer Chimera Enhances Targeted Degradation of Membrane Protein through Regulating Cell Autophagy
10.1021/jacs.5c05456 · 2025 · External reference
Targeted Degradation of Alpha-Synuclein by Autophagosome-Anchoring Chimera Peptides
10.1021/acs.jmedchem.3c01303 · 2023 · External reference
Autophagy-Activating Nanoautophagosome-Tethering Compounds for Targeted Protein Degradation Specifically in Tumor Cells
10.1021/acsmacrolett.4c00789 · 2025 · External reference
Transferrin receptor targeting chimeras for membrane protein degradation
10.1038/s41586-024-07947-3 · 2024 · External reference
LYTACs that engage the asialoglycoprotein receptor for targeted protein degradation
10.1038/s41589-021-00770-1 · 2021 · External reference
Designed endocytosis-inducing proteins degrade targets and amplify signals
10.1038/s41586-024-07948-2 · 2024 · External reference
Polyvalent folate receptor-targeting chimeras for degradation of membrane proteins
10.1038/s41589-025-01924-1 · 2025 · External reference
Development of Integrin-Facilitated Bispecific Aptamer Chimeras for Membrane Protein Degradation
10.1021/jacs.4c04794 · 2024 · External reference
Lysosome Targeting Chimaeras for Glut1-Facilitated Targeted Protein Degradation
10.1021/jacs.4c02463 · 2024 · External reference
Target and tissue selectivity of PROTAC degraders
10.1039/d2cs00200k · 2022 · External reference
Advancing targeted protein degradation for cancer therapy
10.1038/s41568-021-00365-x · 2021 · External reference
Targeted protein degradation: expanding the toolbox
10.1038/s41573-019-0047-y · 2019 · External reference
Targeted Protein Degradation Induced by HEMTACs Based on HSP90
10.1021/acs.jmedchem.2c01648 · 2022 · External reference
Targeted protein degradation via cellular trafficking of nanoparticles
10.1038/s41565-024-01801-3 · 2024 · External reference
Harnessing the Lysosomal Sorting Signals of the Cation-Independent Mannose-6-Phosphate Receptor for Targeted Degradation of Membrane Proteins
10.1021/jacs.3c07687 · 2023 · External reference
Lysosome-Targeting Protein Degradation Through Endocytosis Pathway Triggered by Polyvalent Nano-Chimera for AD Therapy
10.1002/adma.202411061 · 2025 · External reference
Intelligent Modular DNA Lysosome-Targeting Chimera Nanodevice for Precision Tumor Therapy
10.1021/jacs.4c10010 · 2024 · External reference
A Bifunctional Lysosome-Targeting Chimera Nanoplatform for Tumor-Selective Protein Degradation and Enhanced Cancer Immunotherapy
10.1002/adma.202417942 · 2025 · External reference
Nano-LYTACs for Degradation of Membrane Proteins and Inhibition of CD24/Siglec-10 Signaling Pathway
10.1002/advs.202305364 · 2023 · External reference
Sonodynamic Nano-LYTACs Reverse Tumor Immunosuppressive Microenvironment for Cancer Immunotherapy
10.1021/jacs.4c13022 · 2024 · External reference
Targeted Protein Degradation and Delivery Strategies in the Context of Neurological Disorders
10.1021/acsnano.6c04420 · 2026 · External reference
Supramolecular artificial Nano-AUTACs enable tumor-specific metabolism protein degradation for synergistic immunotherapy
10.1126/sciadv.adn8079 · 2024 · External reference
Engineered bioorthogonal POLY-PROTAC nanoparticles for tumour-specific protein degradation and precise cancer therapy
10.1038/s41467-022-32050-4 · 2022 · External reference
Engineering Metal-Organic-Framework-Based STING Nanoagonists for PROTAC-Enhanced Cancer Chemo-Metalloimmunotherapy
10.1002/advs.202515006 · 2026 · External reference
Sequential responsive nano-PROTACs for precise intracellular delivery and enhanced degradation efficacy in colorectal cancer therapy
10.1038/s41392-024-01983-1 · 2024 · External reference
Synergizing CXCL9 with BRD4-PROTAC Using Nanochaperone Boosts Robust T Cell-Dependent Antitumor Immune Responses for Cancer Immunotherapy
10.1002/adfm.202314203 · 2024 · External reference
A Self-Assembling LYTAC Mediates CTGF Degradation and Remodels Inflammatory Tumor Microenvironment for Triple-Negative Breast Cancer Therapy
10.1002/advs.202500311 · 2025 · External reference
A self-assembled affibody-PROTAC conjugate nanomedicine for targeted cancer therapy
10.1007/s12274-024-6974-x · 2024 · External reference
Biomimetic Hybrid PROTAC Nanovesicles Block Multiple DNA Repair Pathways to Overcome Temozolomide Resistance Against Orthotopic Glioblastoma
10.1002/adma.202504253 · 2025 · External reference
Anti-tumor immunotherapy using engineered bacterial outer membrane vesicles fused to lysosome-targeting chimeras mediated by transferrin receptor
10.1016/j.chembiol.2024.01.002 · 2024 · External reference
Checkpoint Nano-PROTACs for Activatable Cancer Photo-Immunotherapy
10.1002/adma.202208553 · 2023 · External reference
A region-confined PROTAC nanoplatform for spatiotemporally tunable protein degradation and enhanced cancer therapy
10.1038/s41467-024-50735-w · 2024 · External reference
Light-Triggered PROTAC Nanoassemblies for Photodynamic IDO Proteolysis in Cancer Immunotherapy
10.1002/adma.202405475 · 2024 · External reference
Near-Infrared-Activatable PROTAC Nanocages for Controllable Target Protein Degradation and On-Demand Antitumor Therapy
10.1021/acs.jmedchem.3c00587 · 2023 · External reference
PROTAC Prodrug-Integrated Nanosensitizer for Potentiating Radiation Therapy of Cancer
10.1002/adma.202314132 · 2024 · External reference
DNA nanoflower Oligo-PROTAC for targeted degradation of FUS to treat neurodegenerative diseases
10.1038/s41467-025-60039-2 · 2025 · External reference
In Vivo Self-Assembly of PROTACs by Bioorthogonal Chemistry for Precision Cancer Therapy
10.1002/anie.202421713 · 2025 · External reference
Factors governing tumor penetration of nanomedicines: intrinsic and extrinsic determinants
10.1039/d5nr04462f · 2026 · External reference
The Nanocarrier Landscape—Evaluating Key Drug Delivery Vehicles and Their Capabilities: A Translational Perspective
10.1021/acsami.5c07366 · 2025 · External reference
Polyethylene Glycol Immunogenicity: Theoretical, Clinical, and Practical Aspects of Anti-Polyethylene Glycol Antibodies
10.1021/acsnano.1c05922 · 2021 · External reference
Proteolysis-targeting chimera (PROTAC) nanomedicines toward cancer treatment: From synthesis to therapeutic delivery
10.1016/j.biomaterials.2025.123621 · 2026 · External reference
Advancing Proteolysis Targeting Chimera (PROTAC) Nanotechnology in Protein Homeostasis Reprograming for Disease Treatment
10.1021/acsnano.4c09800 · 2024 · External reference
PEG–PLGA copolymers: Their structure and structure-influenced drug delivery applications
10.1016/j.jconrel.2014.03.026 · 2014 · External reference
PROTAC Delivery Strategies for Overcoming Physicochemical Properties and Physiological Barriers in Targeted Protein Degradation
10.3390/pharmaceutics17040501 · 2025 · External reference
Current status on the biodegradability of acrylic polymers: microorganisms, enzymes and metabolic pathways involved
10.1007/s00253-020-11073-1 · 2021 · External reference
Synthesis of mesoporous silica nanoparticles
10.1039/c3cs35405a · 2013 · External reference
Strategies to Regulate the Degradation and Clearance of Mesoporous Silica Nanoparticles: A Review
10.2147/ijn.s451919 · 2024 · External reference
Mitigating metal-organic framework (MOF) toxicity for biomedical applications
10.1016/j.cej.2023.144400 · 2023 · External reference
Guest Leakage from ZIF-8 Particles under Drug Delivery Conditions: Quantitative Characterization and Guest-Induced Framework Stabilization
10.1021/acs.jpcc.1c03876 · 2021 · External reference
Anti-PEG antibodies in the clinic: Current issues and beyond PEGylation
10.1016/j.jconrel.2016.06.040 · 2016 · External reference
Understanding and controlling the interaction of nanomaterials with proteins in a physiological environment
10.1039/c1cs15233e · 2012 · External reference
Physical traits of cancer
10.1126/science.aaz0868 · 2020 · External reference
Stimuli-responsive clustered nanoparticles for improved tumor penetration and therapeutic efficacy
10.1073/pnas.1522080113 · 2016 · External reference
Endocytosis: The Nanoparticle and Submicron Nanocompounds Gateway into the Cell
10.3390/pharmaceutics12040371 · 2020 · External reference
The role of surface charge in cellular uptake and cytotoxicity of medical nanoparticles
10.2147/ijn.s36111 · 2012 · External reference
A Decade of the Protein Corona
10.1021/acsnano.7b08008 · 2017 · External reference
Hydrophobic blocks of PEG-conjugates play a significant role in the accelerated blood clearance (ABC) phenomenon
10.1016/j.jconrel.2012.11.016 · 2013 · External reference
Engineering brain-penetrant PROTACs: Bridging molecular design and CNS delivery
10.1016/j.addr.2026.115876 · 2026 · External reference
Self-Assembled Molecular Glue Prodrug System for Enhanced Synergistic Tumor Therapy by Combining CDK12 Protein Degradation and Immunotherapy
10.1021/acsami.5c02939 · 2025 · External reference
Synergistic Proteolysis Targeting Chimera Chemotherapy Conjugate for Potent Non-small Cell Lung Cancer Treatment
10.1021/acsami.5c18202 · 2025 · External reference
MMP-2-triggered, mitochondria-targeted PROTAC-PDT therapy of breast cancer and brain metastases inhibition
10.1038/s41467-024-54854-2 · 2024 · External reference
Investigating the optimal size of anticancer nanomedicine
10.1073/pnas.1411499111 · 2014 · External reference
Enhancing Tumor Penetration of Nanomedicines
10.1021/acs.biomac.7b00068 · 2017 · External reference
Size-Dependent Regulation of Intracellular Trafficking of Polystyrene Nanoparticle-Based Drug-Delivery Systems
10.1021/acsami.7b05383 · 2017 · External reference
100th Anniversary of Macromolecular Science Viewpoint: Biological Stimuli-Sensitive Polymer Prodrugs and Nanoparticles for Tumor-Specific Drug Delivery
10.1021/acsmacrolett.0c00488 · 2020 · External reference
Evasion of the accelerated blood clearance phenomenon by polysarcosine coating of liposomes
10.1016/j.jconrel.2020.03.022 · 2020 · External reference
Unmasking CSF protein corona: Effect on targeting capacity of nanoparticles
10.1016/j.jconrel.2021.04.001 · 2021 · External reference
